Neurobiological and Neurocognitive Disturbances in First-episode Schizophrenia

• Status: Completed
• Trial end date: 2008-09-01
• Target enrollment: 0
• Participant gender: All

Summary

We want to relate disturbances in first-episode schizophrenic patients in serotonin 5-HT2A receptors, brain structure, brain function, and information processing to each other and to psychopathology. Additionally, we want to examine the influence of 5-HT2A receptor blockade on these disturbances. We expect disturbances in the serotonergic system at baseline to correlate with specific structural and functional changes and with disruption in information processing as measured with psychophysiological and neurocognitive methods - and we expect 5-HT2A receptor blockade to reverse some of the functional and cognitive impairments. We do not expect any effect of treatment on brain structure

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Birte Glenthoj
• Collaborators: AstraZeneca; Copenhagen Hospital Corporation; Copenhagen University Hospital, Hvidovre; Glostrup University Hospital, Copenhagen; Rigshospitalet, Denmark; The Danish Medical Research Council; University of Copenhagen
• Treatments: Quetiapine Fumarate

Criteria

Inclusion Criteria:

• First-episode schizophrenia. The controls are matched for age, gender and parental socioeconomic status

Exclusion Criteria:

• Previous antipsychotic treatment, mental retardation, organic brain damage, and for the controls a psychiatric diagnosis or first-degree relatives with a psychiatric diagnosis